Related references
Note: Only part of the references are listed.European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors
Mariella D'Adda et al.
CANCER (2019)
MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia
Simone Claudiani et al.
HAEMATOLOGICA (2019)
Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay
Lasse Kjaer et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview
Michele Baccarani et al.
LEUKEMIA (2019)
Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline
Anna H. Schuh et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Chronic Myeloid Leukemia, Version 1.2019 Clinical Practice Guidelines in Oncology
Jerald P. Radich et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort
Naranie Shanmuganathan et al.
BLOOD (2018)
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib
Markus Pfirrmann et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
Katia Borgia Barbosa Pagnano et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors
Preetesh Jain et al.
BLOOD (2016)
A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR
H. White et al.
LEUKEMIA (2015)
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
Benjamin Hanfstein et al.
HAEMATOLOGICA (2014)
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Fast-mode duplex qPCR for BCR-ABL1 molecular monitoring: Innovation, automation, and harmonization
Gareth Gerrard et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction
Jian Ye et al.
BMC BIOINFORMATICS (2012)
Standardized definitions of molecular response in chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2012)
Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia
Letizia Foroni et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Guoqing Wei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study
Francis J. Giles et al.
EXPERT REVIEW OF HEMATOLOGY (2010)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories
M. C. Mueller et al.
LEUKEMIA (2008)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes et al.
BLOOD (2006)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML)
RM Arana-Trejo et al.
CLINICAL AND LABORATORY HAEMATOLOGY (2002)
Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia
J Kaeda et al.
ACTA HAEMATOLOGICA (2002)
Share Paper
